New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
08:08 EDTLLYEli Lilly's Cyramza for liver cancer did not meet Phase III primary endpoint
Eli Lilly announced that the Phase III REACH trial of Cyramza in patients with hepatocellular carcinoma or liver cancer, did not meet its primary endpoint; overall survival favored the Cyramza arm but was not statistically significant. There were meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression. The trial compared Cyramza plus best supportive care to placebo plus best supportive care as a second-line treatment in patients with hepatocellular carcinoma after being treated with sorafenib in the first-line setting. No Phase III study of liver cancer has been able to demonstrate improved survival in the second-line setting. Lilly plans to present data from the REACH trial at a scientific meeting later this year.
News For LLY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 12, 2016
07:04 EDTLLYUK High Court rules against Eli Lilly in Alimta vitamin lawsuit
Subscribe for More Information
February 11, 2016
07:08 EDTLLYIncyte sees epacadostat entering Phase 3 during 1H16
Incyte (INCY) said its position in the field of JAK inhibition is demonstrated by the ongoing commercial success of Jakafi and by the recent submissions, by Eli Lilly and Company (LLY), seeking regulatory approval of baricitinib for the treatment of rheumatoid arthritis. Baricitinib was licensed to Lilly by Incyte, and met the primary endpoint in all four of its global Phase 3 studies. If approved, Lilly expects to launch baricitinib in early 2017. In addition, epacadostat, Incyte's first-in-class IDO1 inhibitor, is expected to enter Phase 3 during the first half of 2016 in first-line advanced or metastatic melanoma in combination with Merck & Co's pembrolizumab. Multiple Phase 2, tumor-specific, expansion cohorts of epacadostat in combination with anti-PD-1 and anti-PD-L1 checkpoint modulators are also underway.
February 8, 2016
06:28 EDTLLYPharma trade group rolls out ad campaign aimed at lawmakers, WSJ says
The pharmaceutical industry is launching a new ad campaign with the intention of improving its reputation with lawmakers in an effort to lobby against drug price restrictions, the Wall Street Journal reports. The industry's biggest trade group the Pharmaceutical Research and Manufacturers of America, or PhRMA, says it plans to spend several million dollars this year, and 10% more than it spent last year, on digital, radio, and print advertisements that highlight the sector's role in developing new drugs and advancing medical science, the report says. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Reference Link
February 1, 2016
06:18 EDTLLYTransition Therapeutics announces results from Phase 2 clinical study of TT401
Subscribe for More Information
06:11 EDTLLYTransition Therapeutics reports results from Phase 2 clinical study of TT401
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use